Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
- Autores
- Gonzalez Polo, Virginia; Pucci Molineris, Melisa Eliana; Cervera, Victorio; Gambaro, Sabrina Eliana; Yantorno, Silvina E.; Descalzi, Valeria; Tiribelli, Claudio; Gondolesi, Gabriel Eduardo; Meier, Dominik
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Introduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target.
Consejo Nacional de Investigaciones Científicas y Técnicas
Facultad de Ciencias Médicas - Materia
-
Ciencias Médicas
Liver disease
ILC2
Autoimmune hepatitis
Steatohepatitis
Viral hepatitis - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by-nc-nd/4.0/
- Repositorio
.jpg)
- Institución
- Universidad Nacional de La Plata
- OAI Identificador
- oai:sedici.unlp.edu.ar:10915/162649
Ver los metadatos del registro completo
| id |
SEDICI_49848d0c2d1ac5f8a797aa0c5314a0a0 |
|---|---|
| oai_identifier_str |
oai:sedici.unlp.edu.ar:10915/162649 |
| network_acronym_str |
SEDICI |
| repository_id_str |
1329 |
| network_name_str |
SEDICI (UNLP) |
| spelling |
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosisGonzalez Polo, VirginiaPucci Molineris, Melisa ElianaCervera, VictorioGambaro, Sabrina ElianaYantorno, Silvina E.Descalzi, ValeriaTiribelli, ClaudioGondolesi, Gabriel EduardoMeier, DominikCiencias MédicasLiver diseaseILC2Autoimmune hepatitisSteatohepatitisViral hepatitisIntroduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target.Consejo Nacional de Investigaciones Científicas y TécnicasFacultad de Ciencias Médicas2019-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf366-372http://sedici.unlp.edu.ar/handle/10915/162649enginfo:eu-repo/semantics/altIdentifier/issn/1665-2681info:eu-repo/semantics/altIdentifier/doi/10.1016/j.aohep.2018.12.001info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:42:46Zoai:sedici.unlp.edu.ar:10915/162649Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:42:46.387SEDICI (UNLP) - Universidad Nacional de La Platafalse |
| dc.title.none.fl_str_mv |
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis |
| title |
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis |
| spellingShingle |
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis Gonzalez Polo, Virginia Ciencias Médicas Liver disease ILC2 Autoimmune hepatitis Steatohepatitis Viral hepatitis |
| title_short |
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis |
| title_full |
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis |
| title_fullStr |
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis |
| title_full_unstemmed |
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis |
| title_sort |
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis |
| dc.creator.none.fl_str_mv |
Gonzalez Polo, Virginia Pucci Molineris, Melisa Eliana Cervera, Victorio Gambaro, Sabrina Eliana Yantorno, Silvina E. Descalzi, Valeria Tiribelli, Claudio Gondolesi, Gabriel Eduardo Meier, Dominik |
| author |
Gonzalez Polo, Virginia |
| author_facet |
Gonzalez Polo, Virginia Pucci Molineris, Melisa Eliana Cervera, Victorio Gambaro, Sabrina Eliana Yantorno, Silvina E. Descalzi, Valeria Tiribelli, Claudio Gondolesi, Gabriel Eduardo Meier, Dominik |
| author_role |
author |
| author2 |
Pucci Molineris, Melisa Eliana Cervera, Victorio Gambaro, Sabrina Eliana Yantorno, Silvina E. Descalzi, Valeria Tiribelli, Claudio Gondolesi, Gabriel Eduardo Meier, Dominik |
| author2_role |
author author author author author author author author |
| dc.subject.none.fl_str_mv |
Ciencias Médicas Liver disease ILC2 Autoimmune hepatitis Steatohepatitis Viral hepatitis |
| topic |
Ciencias Médicas Liver disease ILC2 Autoimmune hepatitis Steatohepatitis Viral hepatitis |
| dc.description.none.fl_txt_mv |
Introduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target. Consejo Nacional de Investigaciones Científicas y Técnicas Facultad de Ciencias Médicas |
| description |
Introduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target. |
| publishDate |
2019 |
| dc.date.none.fl_str_mv |
2019-03-01 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Articulo http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://sedici.unlp.edu.ar/handle/10915/162649 |
| url |
http://sedici.unlp.edu.ar/handle/10915/162649 |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/issn/1665-2681 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.aohep.2018.12.001 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) |
| dc.format.none.fl_str_mv |
application/pdf 366-372 |
| dc.source.none.fl_str_mv |
reponame:SEDICI (UNLP) instname:Universidad Nacional de La Plata instacron:UNLP |
| reponame_str |
SEDICI (UNLP) |
| collection |
SEDICI (UNLP) |
| instname_str |
Universidad Nacional de La Plata |
| instacron_str |
UNLP |
| institution |
UNLP |
| repository.name.fl_str_mv |
SEDICI (UNLP) - Universidad Nacional de La Plata |
| repository.mail.fl_str_mv |
alira@sedici.unlp.edu.ar |
| _version_ |
1844616297240854528 |
| score |
13.070432 |